The SUCCESSOR-1 trial closes for recruitment in about four months. You can watch a very short video about it and results so far here https://www.youtube.com/watch?v=gbi9fHdmxmQ
The trial is Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) versus Pomalidomide, Bortezomib and Dexamethasone (PVd) for patients with relapsed or refractory multiple myeloma.
You can read more about the trial, including the sites, here: https://clinicaltrials.gov/study/NCT05519085
The trial is at three sites in New Zealand (Dunedin, Tauranga and Auckland hospitals) and closes in a couple of months. To be eligible you need to have received between 1 to 3 prior lines of therapy, have had prior lenalidomide exposure and can not have had pomalidomide before.
If you are interested in the trial please ask your haematologist to provide you a referral to the nearest site investigator listed. You contact the listed site yourselves but may need a referral letter. If you search “New Zealand” on page at the link above you’ll find the NZ sites but we have screen shotted them below too.
We have asked if BMS (the company that makes the treatment – they also make Revlimid branded lenalidomide) will cover transport costs for those who are not in the areas where the trail is being run. They have said there are no limits set for road travel and in some instances, BMS can cover flights, but these require pre-approval by BMS. So if you are in a different area, you may be able to have transport covered.
